NCT05664217 2025-02-13
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics
Phase 2/3 Terminated
Nektar Therapeutics
Alexion Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Gilead Sciences
Celgene
Chiron Corporation